---
title: "Hengrui Announces Drug Inclusions in China’s 2026 NRDL"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305570916.md"
description: "Jiangsu Hengrui Pharmaceuticals announced that three of its drugs—Zeprumetostat, Ruzinurad Sodium, and Henagliflozin/Retagliptin/Metformin SR Tablets (II)—were newly included in China’s 2026 National Reimbursement Drug List (NRDL). Additionally, a new indication for Trastuzumab Deruxtecan was added, Dalpiciclib Isethionate was renewed with new indications, and several other products were listed."
datetime: "2026-11-15T11:07:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305570916.md)
  - [en](https://longbridge.com/en/news/305570916.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305570916.md)
generator: "portal-rs"
---

# Hengrui Announces Drug Inclusions in China’s 2026 NRDL

The latest update is out from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ).

Three Hengrui medicines—Zeprumetostat Tablets, Ruzinurad Sodium Tablets and Henagliflozin/Retagliptin/Metformin Sustained-Release Tablets (II)—were included in China’s National Reimbursement Drug List for the first time after negotiations with the National Healthcare Security Administration. A new indication for Trastuzumab Rezetecan for Injection was also included, while Dalpiciclib Isethionate Tablets were renewed and included with new indications.

The announcement records expanded or renewed NRDL coverage for several Hengrui products under China’s 2026 reimbursement catalog. It also lists additional medicines, including Henagliflozin Proline Tablets, Rezvilutamide Tablets, Tegileridine Fumarate Injection, Oteseconazole Capsules, Henagliflozin/Metformin Sustained-Release Tablets, Camrelizumab for Injection and Pregabalin.

### Related Stocks

- [01276.HK](https://longbridge.com/en/quote/01276.HK.md)
- [600276.CN](https://longbridge.com/en/quote/600276.CN.md)

## Related News & Research

- [Hengrui Pharma reports 88.9% rise in 2026 third-quarter profit on licensing deals](https://longbridge.com/en/news/303205414.md)
- [Hengrui presenta investigaciones innovadoras en el Congreso ESMO 2026](https://longbridge.com/en/news/303511755.md)
- [Jiangsu Hengrui Appoints Zhang Wei as Senior Vice President](https://longbridge.com/en/news/304084639.md)
- [Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value](https://longbridge.com/en/news/302491193.md)
- [From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment](https://longbridge.com/en/news/303322430.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**